These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36964635)

  • 1. CCNE1 is a predictive and immunotherapeutic indicator in various cancers including UCEC: a pan-cancer analysis.
    Zheng X; Chen L; Liu W; Zhao S; Yan Y; Zhao J; Tian W; Wang Y
    Hereditas; 2023 Mar; 160(1):13. PubMed ID: 36964635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A potential immunotherapeutic and prognostic biomarker for multiple tumors including glioma: SHOX2.
    Wu X; Chen H; You C; Peng Z
    Hereditas; 2023 May; 160(1):21. PubMed ID: 37170390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.
    Wei C; Wang B; Peng D; Zhang X; Li Z; Luo L; He Y; Liang H; Du X; Li S; Zhang S; Zhang Z; Han L; Zhang J
    Front Immunol; 2022; 13():849592. PubMed ID: 35444654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
    Huang S; Sun L; Hou P; Liu K; Wu J
    Front Immunol; 2022; 13():944898. PubMed ID: 36148220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-omics analysis of the oncogenic value of copper Metabolism-Related protein COMMD2 in human cancers.
    Tai P; Wang Z; Chen X; Chen A; Gong L; Cheng Y; Cao K
    Cancer Med; 2023 May; 12(10):11941-11959. PubMed ID: 36205192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin targets a YAP1-TEAD4 complex via AMPKα to regulate CCNE1/2 in bladder cancer cells.
    Wu Y; Zheng Q; Li Y; Wang G; Gao S; Zhang X; Yan X; Zhang X; Xie J; Wang Y; Sun X; Meng X; Yin B; Wang B
    J Exp Clin Cancer Res; 2019 Aug; 38(1):376. PubMed ID: 31455378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-Cancer Analysis Revealed
    Liu J; Wang Y; Yin J; Yang Y; Geng R; Zhong Z; Ni S; Liu W; Du M; Yu H; Bai J
    J Oncol; 2022; 2022():3477148. PubMed ID: 35069733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCNE1 Promotes Progression and is Associated with Poor Prognosis in Lung Adenocarcinoma.
    Ma G; Yang L; Dong J; Zhang L
    Curr Pharm Biotechnol; 2022; 23(9):1168-1178. PubMed ID: 34792009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium.
    Pils D; Bachmayr-Heyda A; Auer K; Svoboda M; Auner V; Hager G; Obermayr E; Reiner A; Reinthaller A; Speiser P; Braicu I; Sehouli J; Lambrechts S; Vergote I; Mahner S; Berger A; Cacsire Castillo-Tong D; Zeillinger R
    Eur J Cancer; 2014 Jan; 50(1):99-110. PubMed ID: 24176298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of CCNE1 expression suppresses cell proliferation and sensitizes gastric carcinoma cells to Cisplatin.
    Zhang C; Zhu Q; Gu J; Chen S; Li Q; Ying L
    Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31072916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Integrated Analysis Identified TAGLN2 As an Oncogene Indicator Related to Prognosis and Immunity in Pan-Cancer.
    Pan T; Wang S; Wang Z
    J Cancer; 2023; 14(10):1809-1836. PubMed ID: 37476180
    [No Abstract]   [Full Text] [Related]  

  • 14. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
    Ayhan A; Kuhn E; Wu RC; Ogawa H; Bahadirli-Talbott A; Mao TL; Sugimura H; Shih IM; Wang TL
    Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
    Chan AM; Enwere E; McIntyre JB; Wilson H; Nwaroh C; Wiebe N; Ou Y; Liu S; Wiedemeyer K; Rambau PF; Grevers X; Morris DG; Neri P; Gilks CB; Visser F; Le N; Luo L; Cook LS; Köbel M
    J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.
    Au-Yeung G; Lang F; Azar WJ; Mitchell C; Jarman KE; Lackovic K; Aziz D; Cullinane C; Pearson RB; Mileshkin L; Rischin D; Karst AM; Drapkin R; Etemadmoghadam D; Bowtell DD
    Clin Cancer Res; 2017 Apr; 23(7):1862-1874. PubMed ID: 27663592
    [No Abstract]   [Full Text] [Related]  

  • 17. Integrated pan-cancer analysis and experimental verification of the roles of tropomyosin 4 in gastric cancer.
    Guo Q; Zhao L; Yan N; Li Y; Guo C; Dang S; Shen X; Han J; Luo Y
    Front Immunol; 2023; 14():1148056. PubMed ID: 36993958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
    Nakayama N; Nakayama K; Shamima Y; Ishikawa M; Katagiri A; Iida K; Miyazaki K
    Cancer; 2010 Jun; 116(11):2621-34. PubMed ID: 20336784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long Non-coding RNA LINC00473 Promotes Breast Cancer Progression
    Zhang C; Yang T
    Protein Pept Lett; 2023; 30(1):72-84. PubMed ID: 36305147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.
    Etemadmoghadam D; Au-Yeung G; Wall M; Mitchell C; Kansara M; Loehrer E; Batzios C; George J; Ftouni S; Weir BA; Carter S; Gresshoff I; Mileshkin L; Rischin D; Hahn WC; Waring PM; Getz G; Cullinane C; Campbell LJ; Bowtell DD
    Clin Cancer Res; 2013 Nov; 19(21):5960-71. PubMed ID: 24004674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.